PALB2-related cancer predisposition
MONDO:0700272Hereditary cancer predisposition due to variation(s) in the PALB2 gene. Pathogenic germline variation in PALB2 confers an autosomal dominant predisposition to tumor formation at multiple primary sites, including breast cancer, ovarian cancer, and pancreatic cancer.
46 clinical trials for this condition and its sub-types, 14 tagged with PALB2-related cancer predisposition itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of PALB2-related cancer predisposition
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis early-phase study tests a combination of two oral drugs, olaparib and ASTX727, in adults with advanced solid tumors that have mutations in genes like BRCA1, BRCA2, PALB2, ATM, or CHEK2. The main goals are to find the safest dose and to check for side effects. About 18 partic…
Phase 1 • Sponsor: Varun Monga, MBBS • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for Hard-to-Treat pancreatic cancer: targeted drug combo shows promise
Disease control OngoingThis study compares a new three-drug combination (NABPLAGEM) against a standard two-drug chemo regimen for people with advanced pancreatic cancer that has spread and carries a BRCA or PALB2 gene mutation. The trial enrolls 10 participants whose cancer worsened after initial treat…
Phase 2/3 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Cancer drug targets BRCA mutations beyond breast and ovarian
Disease control OngoingThis phase 2 trial tests the drug talazoparib in 150 people with advanced cancers that have not responded to standard treatments. Participants must have specific gene changes in BRCA1, BRCA2, or related DNA repair genes. The drug works by blocking an enzyme that helps cancer cell…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Promising prostate cancer trial for hispanic and black patients pulled before start
Disease control CancelledThis was a phase 2 trial testing a combination of niraparib and abiraterone plus prednisone for metastatic hormone-sensitive prostate cancer in Hispanic/Latino and Black patients with specific gene mutations. The study aimed to enroll 64 people but was withdrawn before any partic…
Phase 2 • Sponsor: Qian Qin • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Targeted drug olaparib tested in breast cancer patients with DNA repair flaws
Disease control OngoingThis phase 2 study tests the drug olaparib in 114 people with metastatic breast cancer whose tumors have mutations in certain DNA repair genes (like BRCA1, BRCA2, ATM, PALB2, and others). Olaparib is a PARP inhibitor that may kill cancer cells by blocking their ability to fix dam…
Phase 2 • Sponsor: Beth Israel Deaconess Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New study hopes to outsmart pancreatic cancer by gathering clues
Knowledge-focused OngoingThis study collects health information and test results from 317 people at high risk for pancreatic cancer, including those with cysts, genetic syndromes, or other risk factors. Researchers aim to build a database to find better ways to detect the disease early or prevent it. No …
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Genetic counseling by phone may ease cancer fears in High-Risk women
Knowledge-focused PausedThis study looks at whether watching an online genetics video, with or without phone counseling from a genetic counselor, can reduce the stress women feel about their cancer risk. It involves 5,200 women aged 30 or older who have had triple-negative breast cancer and still have a…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC